These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21121778)

  • 1. Opening the gate for genomics data into clinical research: a use case in managing patients' DNA samples from the bench to drug development.
    Matteson S; Paulauskis J; Foisy S; Hall S; Duval M
    Pharmacogenomics; 2010 Nov; 11(11):1603-12. PubMed ID: 21121778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches.
    Yengi LG
    Pharmacogenomics; 2005 Mar; 6(2):185-92. PubMed ID: 15882137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ontogeny and drug metabolism in newborns.
    Dotta A; Chukhlantseva N
    J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating genomics across drug discovery and development.
    Debouck C
    Toxicol Lett; 2009 Apr; 186(1):9-12. PubMed ID: 18930125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in pharmacogenomics technologies.
    Bhasker CR; Hardiman G
    Pharmacogenomics; 2010 Apr; 11(4):481-5. PubMed ID: 20350126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Affymetrix DMET platform and pharmacogenetics in drug development.
    Deeken J
    Curr Opin Mol Ther; 2009 Jun; 11(3):260-8. PubMed ID: 19479659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacogenomics genomics approaches to optimizing drug therapy].
    Shi J; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Apr; 19(2):156-8. PubMed ID: 11941596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biobanking and pharmacogenomics.
    McCarty CA; Wilke RA
    Pharmacogenomics; 2010 May; 11(5):637-41. PubMed ID: 20415552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomics and transcriptomics in drug discovery.
    Dopazo J
    Drug Discov Today; 2014 Feb; 19(2):126-32. PubMed ID: 23773860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DMET microarray technology for pharmacogenomics-based personalized medicine.
    Burmester JK; Sedova M; Shapero MH; Mansfield E
    Methods Mol Biol; 2010; 632():99-124. PubMed ID: 20217574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics.
    Mousses S; Kiefer J; Von Hoff D; Trent J
    Oncogene; 2008 Dec; 27 Suppl 2():S58-66. PubMed ID: 19956181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Genomic Technologies in Clinical Pharmacology Research.
    León-Cachón RB; Ascacio-Martínez JÁ; Gómez-Silva M; Piñeyro-Garza E; González-González JG; Pogue G; Simón-Buela L; Barrera-Saldaña HA
    Rev Invest Clin; 2015; 67(4):212-8. PubMed ID: 26426586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progress.
    Maitland-van der Zee AH; Aitchison K; Kirchheiner J;
    Eur J Pharm Sci; 2007 Jul; 31(3-4):151-5. PubMed ID: 17452095
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
    Fischer HP
    Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.